Edition:
United Kingdom

Immunovia AB (publ) (IMMNOV.ST)

IMMNOV.ST on Stockholm Stock Exchange

85.70SEK
11:13am GMT
Change (% chg)

-0.80kr (-0.92%)
Prev Close
86.50kr
Open
86.50kr
Day's High
87.20kr
Day's Low
85.70kr
Volume
7,439
Avg. Vol
18,852
52-wk High
123.25kr
52-wk Low
75.50kr

Latest Key Developments (Source: Significant Developments)

Immunovia Q3 net loss widens to SEK 11.6 mln‍​
Friday, 10 Nov 2017 

Nov 10 (Reuters) - IMMUNOVIA AB (PUBL) :NET SALES FOR Q3 2017 WERE SEK 27 THOUSAND (5 K)‍​.THE NET LOSS FOR Q3 2017 WAS SEK 11,589 THOUSAND (-4,048 K)‍​.  Full Article

Immunovia gets SEK 4.9 mln grant from Swelife Accelerator Innovation Program
Monday, 30 Oct 2017 

Oct 30 (Reuters) - IMMUNOVIA AB (PUBL) ::IMMUNOVIA RECEIVES SEK4.9 MILLION GRANT FROM SWELIFE ACCELERATOR INNOVATION PROGRAM.  Full Article

Immunovia starts cooperation with ‍Linköping University Medical Faculty ​
Monday, 23 Oct 2017 

Oct 23 (Reuters) - IMMUNOVIA AB (PUBL) :STARTS COOPERATION WITH ‍LINKÖPING UNIVERSITY MEDICAL FACULTY ​.  Full Article

Immunovia holdig detailed talks about participation in large consortium
Monday, 5 Sep 2016 

Immunovia AB (publ) :Immunovia holdig detailed talks about participation in a large consortium that will address the largest risk group for pancreatic cancer.  Full Article

Immunovia H1 operating loss widens to SEK 5.4 million
Wednesday, 24 Aug 2016 

Immunovia publ AB : H1 net sales 66,000 Swedish crowns ($7,870) versus 59,000 crowns year ago .H1 operating loss 5.4 million crowns versus loss 3.8 million crowns year ago.  Full Article

Immunovia intends to apply for listing on Nasdaq Stockholm's Main Market
Tuesday, 16 Aug 2016 

Immunovia publ AB :Announces intention to apply during H1 2017 for listing on Nasdaq Stockholm's Main Market.  Full Article

Immunovia: 96 pct of early stage pancreatic cancer patients detected
Monday, 30 May 2016 

Immunovia Publ AB :96 percent of early stage pancreatic cancer patients detected in a clinical validation study with a North American sample cohort.  Full Article

Immunovia AB partners with healthcare consulting services firm
Wednesday, 9 Mar 2016 

Immunovia AB:Announces agreement with Ehlers, Ehlers and Partner to develop and drive market access strategy of IMMray PanCan-d in Germany.Under the agreement, Ehlers, Ehlers and Partner will provide advise on strategy and will counsel Immunovia in gaining entry into the German market of IMMray PanCan-d, the test developed for early diagnosis of pancreatic cancer.  Full Article

BRIEF-Immunovia AB Q4 Net Sales Sek ‍​ 26,000 Versus Sek 106,000 Year Ago

* Q4 PRETAX LOSS SEK ‍​ 15.3 MILLION VERSUS LOSS SEK 5.4 MILLION YEAR AGO Source text for Eikon: Further company coverage: (Gdynia Newsroom)